Reports

Ideas That Generate Results

Cancer Monoclonal Antibodies Market to 2015

Cancer Monoclonal Antibodies Market to 2015

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Mar, 2012| No. of Pages : 105

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1500.00
CD-ROM Mail Delivery
US$ 1700.00
Hard Copy Mail Delivery
US$ 1700.00
Electronic Access - Multi-User License
US$ 2200.00

1. Analyst View

2. Research Methodology

3. The Global Burden of Cancer
    3.1 Cancer - A Leading Cause of Death
    3.2 Current and Future Cancer Cases: By Type and Geography
    3.3 Common Causes of Cancer

4. Global Cancer Market Outlook to 2015
    4.1 Current and Future Growth
    4.2 Analysis by Therapeutic Areas

5. Monoclonal Antibodies: Introduction and Working
    5.1 Types of Mabs
          5.1.1 Murine Antibodies
          5.1.2 Chimeric and Humanized Antibodies
          5.1.3 Fully Human Antibodies
    5.2 Conjugated Cancer Therapies using MAbs
          5.2.1 Radioimmunotherapy
          5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)
          5.2.3 Immunoliposomes
          5.2.4 Immunotoxin
          5.2.5 Immunocytokine
    5.3 mAb Therapies
          5.3.1 Avastin/Bevacizumab
          5.3.2 Rituxan/Rituximab
          5.3.3 Herceptin/Trastuzumab
          5.3.4 Erbitux/Cetuximab
          5.3.5 Vectibix/Panitumumab
          5.3.6 Campath/Alemtuzumab
          5.3.7 Zevalin/ Ibritumomab
          5.3.8 Bexxar/Tositumomab
          5.3.9 Arzerra/Ofatumumab

6. Industry Trends and Drivers
    6.1 Strategic Activity Building Up in the Market
    6.2 New Approvals Showing Promising Future
    6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
    6.4 Japan Gearing-up for Cancer Antibodies

7. Global Anti-Neoplastic mAbs Market Outlook to 2015
    7.1 Market Size
    7.2 Anti-Neoplastic mAbs: Approval History and Market Share
    7.3 Anti-Neoplastic mAbs: Current and Future Market Size
          7.3.1 Avastin (Bevacizumab)
          7.3.2 MabThera/Rituxan (Rituximab)
          7.3.3 Herceptin (Trastuzumab)
          7.3.4 Erbitux (Cetuximab)
          7.3.5 Vectibix (Panitumumab)
    7.4 Country-Level Analysis
          7.4.1 US
          7.4.2 Japan
          7.4.3 Europe
    7.5 Market Share of Key Players

8. Pipeline Analysis for Anti-Neoplastic Monoclonal Antibodies

9. Competitive Landscape
    9.1 Roche
    9.2 Immunomedics
    9.3 Bristol-Myers Squibb
    9.4 AstraZeneca
    9.5 Eli Lilly
    9.6 Amgen

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.